All News

Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.

This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.

A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.

In late 2022, Leaf411, a cannabis-trained nurse guidance service, announced that they resumed their affordability program for patients struggling to pay for their medicine. In a recent update, Leaf411 outlined their continued response to requests for assistance they are receiving from across the country.

The study, which began before states started legalizing cannabis, published its results on the impact of a legal cannabis environment on cannabis use and alcohol use disorder.

Josee Guindon, DVM, PhD of Texas Tech University Health Sciences Center, was named as the recipient for this award, which recognizes dedication, perseverance, and skill in studying and researching the endocannabinoid system.

A farmer in Ireland who was arrested for growing and selling cannabis from his farm received a suspended sentence. Currently, cannabis is illegal in Ireland, except within a limited medical program.

A recent study from the University of Connecticut showed that the new “retipping” method of propagation resulted in quality cannabis flowers while using less space.

In results from a recent study, respondents reported that cannabis use led them to decrease their use of pharmacological treatments, including opioids.

Village Farms International, Inc., announced that starting later this month it will increase its global presence by beginning to ship cannabis products to the Israeli medical market.

In December, the US Department of Agriculture (USDA) announced an extension of the deadline for all hemp to be tested for tetrahydrocannabinol (THC) in Drug Enforcement Administration (DEA)-certified facilities only, citing a lack of approved laboratories.

Brittany Griner had been arrested in Moscow, Russia and sentenced to prison for cannabis possession, which is illegal in Russia.

On December 2nd, 2022, President Joe Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act, the first piece of standalone cannabis legislation in US history to become law. It will reportedly streamline a new process for cannabis research applications and for manufacturing products for drug development and allow for a larger amount of legal cannabis for research purposes.

In partnership with the Cannabis Center of Excellence, MCR Labs Massachusetts held their second “Cannabis Science Fair” on the afternoon of December 3rd, 2022, as the final event of their Science Over Stigma campaign.

In their 2022 Census of Agriculture, the US Department of Agriculture will, for the first time, collect and publish data on farmers and producers who grow hemp for fabric, food products, and cannabidiol (CBD).

The Cannabis & Me research study will reportedly study the effects of cannabis on the human brain, particularly in terms of a user’s prior psychological conditions.

International company PQE Group announced in late October their first ever start-up to provide support for medical cannabis.

For the first time, the Association of Official Analytical Collaboration (AOAC) INTERNATIONAL Research Institute granted its Reviewed and Recognized certification to a cannabis potency testing laboratory.

Earlier this month, Committee D37 on Cannabis, a committee within ASTM International, released descriptions of their four new standards for cannabis testing and who they will benefit within the industry.

In a recent announcement, Major League Baseball announced a sponsorship deal with cannabidiol (CBD) company Charlotte’s Web.

The 2022 Canna Pharma Conference was held October 12-13 in San Diego, California.

In a statement released from the White House on October 6, 2022, President Joe Biden announced plans to pardon Federal convictions for simple possession of marijuana and issued a call to review the scheduling of cannabis (1).

The Association of Official Analytical Collaboration (AOAC) INTERNATIONAL announced the winners of more than a dozen awards presented at their Annual Meeting.

Recently, some major food and beverage companies expressed interest in selling products containing cannabidiol (CBD), but the Food and Drug Administration (FDA) have not indicated any regulatory progress.

Cannabis Science Conference East was held in Baltimore, Maryland from September 14-16, 2022. Here we provide a few highlights from the event.

In a presentation for the psychedelics track at Cannabis Science Conference East 2022, Janie Maedler, Vice President of Rylie’s Smile Foundation and President of Rylie’s Sunshine LLC, led a panel discussion with Rylie Maedler, President of Rylie’s Smile and CEO of Rylie’s Sunshine LLC; Rita Lynn Lawrence, a cannabis patient advocate; and University of Miami cannabis epidemiologist Dr. Denise Vidot. The presentation titled “Psychedelics for Beginners” discussed the basics of using psychedelics for treating mental health issues safely and successfully. Here are some highlights from the session.

In his presentation for the psychedelics track at Cannabis Science Conference East 2022, James Schwartz, BSN, LNC, presented “A New Beginning for an Old Therapy: Case Series Review on the Treatment of PTSD and Other Psychiatric Disorders with Psilocybin and Other Psychedelics.” He reviewed the current research and clinical trials studying the effects of psilocybin, plus side effects, potential uses, latest trends, disorders currently being studied, and potential future applications. Schwartz was a trauma trained nurse who worked in the Trauma/Critical Care ICU at Oregon Health and Science University. He is an experienced medical legal consultant and CEO of Cascade High. Here are some highlights from his session.

In his keynote address for the psychedelics track at Cannabis Science Conference East 2022, Dr. Matthew Johnson presented his talk “Psilocybin in the Treatment of Tobacco Addiction,” which reviewed the treatment of substance use disorders with classic psychedelics (5HT2A agonists) including LSD and psilocybin. Dr. Matthew Johnson, PhD, is the Susan Hill Ward Professor of Psychedelics at Johns Hopkins and is one of the world’s most widely published experts on psychedelics. Here are some highlights from his session.